Literature DB >> 16414389

Takayasu's arteritis: operative results and influence of disease activity.

Charles E Fields1, Thomas C Bower, Leslie T Cooper, Tanya Hoskin, Audra A Noel, Jean M Panneton, Timothy M Sullivan, Peter Gloviczki, Kenneth J Cherry.   

Abstract

OBJECTIVES: To determine the short- and long-term outcomes of patients treated operatively for Takayasu's arteritis and the effect of disease activity on results.
METHODS: Forty-two (17%) of the 251 patients enrolled in our Takayasu's arteritis registry between 1975 and 2002 required operation for symptomatic disease. Data were obtained from the registry, patient records, phone correspondence, and written surveys.
RESULTS: There were 38 females and 4 males with a median age of 29 years (range, 12 to 56 years), and 32 (76%) were white. Sixty operations were performed for symptomatic disease. The mean duration of symptoms before operation was 5.6 months (range, 0 to 25 months). Thirteen (31%) patients had active disease and underwent operation for acute presentation or failure of medical management. Thirty-nine patients (93%) had operation for occlusive disease. Twenty-two (52%) patients had involvement of both the great and abdominal aortic branch vessels; 10 (24%) had great vessel disease alone; 9 (21%) had involvement of abdominal arteries; and 1 (2%) had coronary artery disease. There was no operative death, myocardial infarction, major stroke, or renal failure. Three patients had early graft thrombosis, two had a minor stroke, and two developed hyperperfusion syndrome. The median follow-up was 6.7 years (range, 1 month to 19.3 years). Eleven (26%) patients required 15 graft revisions; five of the patients had active disease at the time of initial operation. All early revisions (<1 year) were in patients with active disease. By Kaplan-Meier analysis, freedom from revision at 5 and 10 years was 100% in patients with quiescent disease not requiring steroids (group I, n = 5, 12%), 95% and 81% in patients whose disease was quiescent on steroids (group II, n = 24, 57%), 57% in patients with active disease on steroids (group III, n = 7, 17%), and 33% in patients with active disease and no long-term steroids (group IV, n = 6, 14%) (P < .006). The rate of revision or progression of disease at another site in 5 years was 0% in group 1, 10% in group 2, 57% in group 3, and 67% in group 4 (P < .001) The differences were even more pronounced when an analysis was done on the basis of disease activity alone, irrespective of steroid use. During the follow-up period, 3 of 39 great vessel, 2 of 18 mesenteric/renal, and 1 of 9 aortofemoropopliteal reconstructions occluded. The predicted mortality for patients was 4% at both 5 and 10 years (95% CI) respectively (confidence interval [CI], 0% to 11%) and 10 (CI, 0% to 14%) years, respectively.
CONCLUSIONS: The minority of patients with Takayasu's arteritis require operation. In our predominantly white female patient population, occlusive symptoms were the most common indication for operation. Operation for these selected patients was safe, with no operative mortality, myocardial infarction, major stroke, or renal failure. Patients with active disease requiring operation are more likely to require revision or develop progressive symptomatic disease at another site. Long-term survival is excellent, regardless of disease activity at the time of operation.

Entities:  

Mesh:

Year:  2006        PMID: 16414389     DOI: 10.1016/j.jvs.2005.10.010

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  32 in total

1.  Takayasu's arteritis: clinical features and outcomes of 125 patients in China.

Authors:  Xiao-Liang Cong; Sheng-Ming Dai; Xiang Feng; Zhi-Wei Wang; Qing-Sheng Lu; Liang-Xi Yuan; Xian-Xian Zhao; Dong-Bao Zhao; Zai-Ping Jing
Journal:  Clin Rheumatol       Date:  2010-06-30       Impact factor: 2.980

2.  Impact of revascularization on hypertension in children with Takayasu's arteritis-induced renal artery stenosis: a 21-year review.

Authors:  Taiwo Augustina Ladapo; Priya Gajjar; Mignon McCulloch; Christiaanah Scott; Alp Numanoglu; Peter Nourse
Journal:  Pediatr Nephrol       Date:  2015-02-04       Impact factor: 3.714

3.  Anti-cytokine treatment for Takayasu arteritis: State of the art.

Authors:  Enrico Tombetti; Maria Chiara Di Chio; Silvia Sartorelli; Enrica Bozzolo; Maria Grazia Sabbadini; Angelo A Manfredi; Elena Baldissera
Journal:  Intractable Rare Dis Res       Date:  2014-02

4.  Transradial retrograde percutaneous transluminal angioplasty with stenting of long segment occlusion of subclavian artery.

Authors:  Desabandhu Vinayakumar; Sherief Sulaiman; Cicy Bastian; Sandeep Rajasekharan
Journal:  J Cardiol Cases       Date:  2017-01-20

5.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

6.  Management of the renovascular disease in children with Takayasu arteritis.

Authors:  Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

Review 7.  Advances in the diagnosis, assessment and outcome of Takayasu's arteritis.

Authors:  Fatma Alibaz-Oner; Sibel Zehra Aydin; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

Review 8.  Takayasu arteritis--advances in diagnosis and management.

Authors:  Justin C Mason
Journal:  Nat Rev Rheumatol       Date:  2010-07       Impact factor: 20.543

Review 9.  Recent advances in Takayasu's arteritis.

Authors:  Fatma Alibaz-Öner; Sibel Zehra Aydın; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2015-03-01

10.  Cerebrovascular events in Takayasu arteritis: a multicenter case-controlled study.

Authors:  Priscille Couture; Thibaud Chazal; Charlotte Rosso; Julien Haroche; Anne Léger; Baptiste Hervier; Sandrine Deltour; Zahir Amoura; Fleur Cohen Aubart
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.